. The latter is caused by mutations in the PEX7 gene, encoding a cytosolic receptor involved in the import of a small subset of peroxisomal matrix proteins (Braverman et al., 2002; Motley et al., 2002) . The ZSS disorders include the Zellweger syndrome (ZS, MIM 214100), neonatal adrenoleukodystrophy (NALD, MIM 202370) and infantile Refsum disease (IRD, MIM 266510), which represent a spectrum of disease severity with ZS being the most, and IRD the least severe disorder.
ZSS disorders are autosomal recessive disorders and can be caused by a defect in any of at least 12 different PEX genes (Steinberg et al., 2006) . These PEX genes encode proteins called peroxins that are involved in various stages of peroxisomal protein import and/or the biogenesis of peroxisomes. Severe defects in one of these PEX genes result in a complete absence of functional peroxisomes as observed in the Zellweger Syndrome phenotype. The NALD or IRD phenotypes are often associated with residual peroxisomal functions and/or partial functional peroxisomes (i.e. peroxisomal mosaicism (Wanders and Waterham, 2006; Weller et al., 2003) ). identified that are required for these processes. To study whether human peroxisome biogenesis requires the action of additional peroxins, we set out to assign primary skin fibroblasts from patients diagnosed with a ZSS disorder to different genetic complementation groups. Following the complementation analysis, we performed mutation analysis of the respective PEX genes in a majority of cell lines. We here report the results of our genetic complementation studies in more than 600 cell lines from patients with a Zellweger syndrome spectrum disorder. In addition, we provide an overview of all mutations we identified in these patient cell lines, completed with previously reported mutations in the respective PEX genes. 
Methods

Cell lines
For this study, we used 613 independent primary skin fibroblast cell lines from non-related patients that had been sent to our laboratory since 1985 for diagnostic evaluation and which were diagnosed with a ZSS disorder. The diagnosis is based on metabolite analysis in plasma, which ideally involves analysis of very long chain fatty acids (VLCFAs), bile acid intermediates, phytanic acid, pristanic acid, pipecolic acid and plasmalogens, and/or detailed studies in fibroblasts, including VLCFA analysis, C26:0 and pristanic acid β-oxidation, phytanic acid α-oxidation and dihydroxyacetonephosphate acyltransferase (DHAPAT) activity analysis, and the absence of peroxisomes assessed by on catalase immunofluorescence (IF) microscopy (Wanders and Waterham, 2005) . The cell lines were cultured in DMEM medium (Gibco, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Bio-Whittaker), 100 U/ml penicillin, 100µg/ml streptomycin and 25 mM Hepes buffer with L-glutamine in a humidified atmosphere of 5% CO 2 and at 37°C. In accordance to the institutional guidelines and the Dutch Code of Conduct, identifiable clinical and personal data from the patients were not available for this study.
Genetic complementation assays
To assign cell lines to genetic complementation groups, we used a previously described polyethylene glycol (PEG)-mediated cell fusion assay (Brul et al., 1988 ) and a PEX cDNA transfection assay, specifically developed for this purpose. In the latter assay, ZSS cell lines are co-transfected separately with one of the 12 different PEX cDNAs subcloned in the pcDNA3 expression vector (Invitrogen, Carlsbad, CA) and an eGFP-SKL vector . The eGFP-SKL vector expresses eGFP tagged with the peroxisomal targeting signal -SKL, which allows immediate visual detection of peroxisomes when present. The Deleted: the F o r P e e r R e v i e w 6 transfections were performed with the NHDF Nucleofector Kit (Amaxa, Cologne, Germany) and the Nucleofector Device (Amaxa, Cologne, Germany) using the standard program U-23, which in our hands results in high transfection efficiencies ranging from 70-80% for primary skin fibroblasts. We performed the transfections of cell lines in three subsequent series based on the estimated frequency of the different PEX gene defects. In the first series, we transfected cell lines separately with PEX1, PEX6 and PEX12. Cell lines that were not functionally complemented were then transfected separately with PEX2, PEX10 and PEX26 and finally with PEX5, PEX13 and PEX14. Transfection with PEX3, PEX16 and PEX19 was performed when the patient fibroblasts showed no peroxisomal membrane remnants based on immunofluorescence microscopy (van Grunsven et al., 1999) with antibodies against ALDP (Euromedex, France, Souffelweyersheim), a peroxisomal membrane protein. Cells were examined by means of fluorescence microscopy 48 to 72 hours after transfection to determine the subcellular localization of the peroxisomal reporter protein eGFP-SKL (see also figure 1).
Mutation analysis
Mutation analysis was performed by either sequencing all exons plus flanking intronic sequences of the PEX genes amplified by PCR from genomic DNA or by sequencing PEX cDNAs prepared from total RNA fractions. Genomic DNA was isolated from skin fibroblasts using the NucleoSpin Tissue genomic DNA purification kit (Macherey-Nagel, Germany, Düren). Total RNA was isolated from skin fibroblasts using Trizol (Invitrogen, Carlsbad, CA) extraction, after which cDNA was prepared using a first strand cDNA synthesis kit for RT-PCR (Roche, Mannheim, Germany). All forward and reverse primers (Supp tables S1-11)
were tagged with a -21M13 (5-'TGTAAAACGACGGCCAGT-3') sequence or M13rev (5'-CAGGAAACAGCTATGACC-3') sequence, respectively. PCR fragments were sequenced in two directions using '-21M13' and 'M13rev' primers Mutation analysis of PEX1 (GenBank accession number NM_000466.2) was performed by sequencing the coding region of the PEX1 cDNA and/ or exons amplified from gDNA or by RFLP analysis to identify the frequently occurring c.2528G>A mutation. The RFLP analysis involves PCR amplification using a specific primer set (see Supp Table S1 ) of a 130-bp genomic DNA fragment encompassing the c.2528G/A nuctleotide, followed by restriction analysis with ClaI. The c.2528G>A mutation creates a restriction recognition site for ClaI and thus can be screened for by RFLP analysis. Mutations in the PEX2 gene were identified by sequencing the coding exon 4 from gDNA (NM_000318.2). The PEX3 (NM_003630.2) gene was analyzed by sequencing of the coding region of the PEX3 cDNA. Mutation analysis of 
Results and Discussion
Genetic complementation
Initially, we used a previously reported cell fusion complementation assay (Brul et al., 1988) .
Because this assay is rather laborious, we developed a more rapid and direct complementation assay taking advantage of the known identities of the 12 human PEX genes that can cause a ZSS disorder (for principle see figure 1 ). The PEX cDNA transfection assay worked very well for cell lines displaying complete peroxisome deficiencies, and for cell lines displaying different degrees of peroxisomal mosaicism that are sensitive to culturing at 40ºC, which exacerbates the defect in peroxisome biogenesis (Gootjes et al., 2004b) . We assigned 613 different ZSS cell lines to genetic complementation groups (Table 1) . The results give a representative overview of the spectrum of PEX gene defects among ZSS disorders with PEX1 (MIM602136), PEX6 (MIM601498) and PEX12 (MIM601758) defects being the most common. Although we received ZSS cell lines from different parts of the world, they predominantly (>90%) are from Western European origin and thus the spectrum of PEX gene defects primarily relates to the Western European population.
Somewhat unexpected, all the analyzed ZSS cell lines could be assigned to one of the known genetic complementation groups and no novel complementation group was identified.
In a recent study where 90 cell lines were assigned to genetic complementation groups using a similar approach also no novel complementation groups were identified (Krause et al., 2009 as recently exemplified by a very distinct peroxisomal and mitochondrial fission defect due to a dominant negative mutation in the DLP1 gene . In addition, defects in certain PEX genes may also be without consequences due to gene redundancy. For example, recently 3 human proteins have been reported with a similar function as the yeast PEX4 gene, which is associated with complete peroxisome deficiency in yeast (Grou et al., 2008) . Considering that these proteins are encoded by different genes and each can promote the ubiquitination of PEX5 (MIM600414) on its own, it seems unlikely that a defect in one of these proteins will cause a peroxisomal disorder (Grou et al., 2008) . Finally, although we consider this unlikely, we cannot exclude the possibility that a defect in certain unannotated PEX genes may be embryonic lethal and thus will not be diagnosed.
Mutation analysis
After the assignment of patient cell lines to genetic complementation groups, we performed mutation analysis of the respective PEX genes in 393 of the cell lines. For most genes all coding exons plus flanking intron sequences were analysed by sequencing. In principle, this method will identify all missense and nonsense mutations, small deletions, small duplications and small insertions located in the analysed fragments. However, the presence of large, heterozygous deletions or duplications, or pathogenic mutations located outside the analysed fragments cannot be excluded. The reported mutations are assumed to be pathogenic for the following reasons: 1) They are the only sequence variants identified in the coding regions or flanking intronic sequences of a given PEX gene that was demonstrated to be defective by the fact that peroxisome biogenesis in the corresponding cell line is restored after transfection with the respective PEX cDNA (i.e. a functional assay). 2) The sequence variants are not listed in the SNP database or encountered in more than 100 control chromosomes. (Maxwell et al., 2005) . The most common mutation in PEX1 is a missense mutation in the second ATP-binding domain (c.2528G>A) leading to p.G843D. This mutation reduces the binding between PEX1 and PEX6 and is known for its temperature sensitivity, meaning that when fibroblasts of patients homozygous for G843D are cultured at 30°C, they regain the ability to import catalase and other peroxisomal matrix proteins, as well as the various peroxisomal metabolic functions (Imamura et al., 1998a; Maxwell et al., 2005) . Patients homozygous for the G843D mutation usually present with the milder IRD phenotype. Cells of these patients often display peroxisomal mosaicism at 37°C, but a complete peroxisome deficiency when cultured at 40°C. The second most common mutation in PEX1 is c.2079_2098insT, which results in a frame shift predicted to cause a truncated PEX1 protein (Collins and Gould, 1999) , although Northern blot analysis showed that this mutation results in low steady state PEX1 mRNA levels (Maxwell et al., 2005) . Patients homozygous for this mutation are affected with the severe ZS phenotype. The c.2926delA mutation is the third most common mutation in PEX1; this mutation leads to a frame shift. When combined with previously reported PEX1 mutations, a total of 88 different mutations have now been identified in the PEX1 gene, of which 34 have not been reported previously. In two cell lines we found three heterozygous mutations after sequencing gDNA (Table 1 ). In the first cell line the following 3 heterozygous mutations were found, p.T526A, p.911_912delCT and p.1885_1886delGT, of which the last two have been reported as pathogenic in literature. The consequence of the p.T526A mutation is unclear, but the threonine at position is a conserved amino acid in Pan troglodytes Deleted: It should be noted that in the vast majority of cell lines we identified either two heterozygous or one homozygous putative pathogenic mutation, in few cell lines we only found one heterozygous mutation after sequencing gDNA, which in most cases appeared homozygously expressed when analyzing the respective PEX cDNA, indicating that the second, unidentified mutation affects gene transcription of mRNA stability. ¶ (chimpanzee), Canis familiaris (dog) and Gallus gallus domesticus (chicken) and the software program Polyphen predicts this amino acid substitution as possibly damaging. In the second cell line, the heterozygous p.V336A, p.S555P and p.R949W missense mutations all affect well conserved amino acids and, according to Polyphen, are predicted to be benign, possibly damaging and probably damaging, respectively, suggesting that p.V336A may be a rare sequence variation. All the novel identified missense mutations are not listed in the SNP database, have not been detected in more than 100 control chromosomes and in fact all affect (well) conserved amino acids. In addition, Polyphen predicts these amino acid substitutions as either possibly damaging or probably damaging.
The PEX2 (MIM170993) gene was the first gene reported to be mutated in ZSS patients. PEX2 is an integral membrane protein with two transmembrane domains and a zincbinding motif, probably involved in the poly-ubiquitination of the peroxisomal import receptor PEX5 (Platta et al., 2009 ). The PEX2 gene contains four exons, but the entire coding region is included in exon 4. One mutation in the PEX2 gene (c.355C>T) was found to be associated with temperature sensitivity: cells cultured at 30°C show partial catalase import (Imamura et al., 1998b) . The patient fibroblasts homozygous for the c.669G>A mutation displayed a mosaic peroxisomal pattern, characterized by import competency of catalase in 30% of the cells (Gootjes et al., 2003; Gootjes et al., 2004a) . In 3 different cell lines, sequence analysis of exon 4 identified only one heterozygous mutation (table 1) . We did not analyze the remaining exons, promoter sequence or PEX2 cDNA of these cell lines. In this study, six novel mutations have been identified, making a total of 17 different mutations currently identified in the PEX2 gene (table 3) . Two novel missense mutation are identified which are not listed in the SNP database, and both affect (well) conserved amino acids. In addition, Polyphen predicts these amino acid substitutions as probably damaging. (MIM603164) is an integral membrane protein with two putative membranespanning domains. The exact function of PEX3 is unclear, but it has been assumed that PEX3 plays a role in insertion of peroxisomal membrane proteins into the peroxisomal membrane based on the absence of peroxisomal ghosts in cell lines with a defect in PEX3 (Ghaedi et al., 2000; Muntau et al., 2000) . In total, six different mutations in PEX3 were identified of which four have been reported previously (table 4). PEX5 is a protein with seven di-aromatic pentapeptide repeats (WxxxF/Y) essential for docking to the peroxisomal membrane and for binding to either PEX13 (MIM601789) or PEX14 (MIM601791), (Saidowsky et al., 2001; Weller et al., 2003) , and with seven tetrapeptide repeats (TPRs) to mediate the interaction with the PTS1 sequence. In humans, two functional protein variants of PEX5 are produced as a result of alternative splicing of the PEX5 mRNA. The longest variant, PEX5L, contains an additional 111bp encoding 37 amino acids, due to alternative splicing of exon 7 (Dodt et al., 2001 ). The shorter protein, PEX5S, has been reported to be exclusively involved in peroxisomal PTS1 protein import, whereas PEX5L mediates both PTS1 and PTS2 protein import. We recently published and discussed the mutations we identified in the PEX5 gene elsewhere (Ebberink et al., 2009b) . These mutations combined with previously reported mutations are listed in table 5.
The PEX6 gene consists of 17 exons and mutations in the PEX6 gene were found to be scattered throughout the whole gene. PEX6 is also a member of the AAA ATPase family and interacts with PEX1. PEX6 is required for import of peroxisomal matrix proteins and/or vesicle fusion. At present, 77 different mutations in PEX6 gene have been identified, a complete overview of which has been reported very recently and thus will not been shown here (Ebberink et al., 2009a) . PEX10 (MIM602859) is an integral membrane protein and contains two transmembrane domains and a C-terminal zinc-binding motif, similar as PEX2 and PEX12. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Two mRNA splice forms of PEX10 have been identified, resulting from the use of a different splice acceptor site at the 3'end of intron 3. The longer form accounts for 10% of the PEX10 mRNA in the cell and appears to be slightly less functional (Warren et al., 2000) . Combined with previously reported PEX10 mutations, 25 different mutations have been identified in the PEX10 gene of which nine have not been reported previously (table 6) (Gootjes et al., 2004c) . We identified two novel missense mutations both affecting well conserved amino acids and Polyphen predicts these amino acid substitutions as probably damaging.
PEX13 is a peroxisomal integral membrane protein with two putative membrane domains. The C-terminus contains an SH3 domain, which binds to pentapeptide repeats 2-4 of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table 8 lists ten different PEX13 mutations of which six have been reported before. The I326T mutation causes a temperature-sensitive biochemical phenotype in fibroblasts: peroxisomes still import residual levels of PTS1 and PTS2 proteins at 37°C but not at elevated temperature (Liu et al., 1999; Shimozawa et al., 1999a) . One novel missense mutation was identified which affects a well conserved amino acid and is probably damaging according to Polyphen.
The PEX14 gene encodes a peroxisomal membrane protein that was initially identified as a peroxisomal docking factor for the PTS1 receptor PEX5 via binding to the aminoterminal WxxxF/Y motifs of PEX5. More recently, it was proposed that PEX14 is also the site from which PEX5 leaves the peroxisomal compartment (Azevedo and Schliebs, 2006) . A mutation in PEX14 is the least common cause of ZZS disorder. Three different mutations have now been identified in the PEX14 gene of which 1 has not been reported previously (table 9 ).
The PEX16 (MIM603360) gene encodes an integral peroxisomal membrane protein involved in peroxisomal membrane assembly. Two different groups of PEX16-defective patients have been reported; patients with a severe clinical presentation of which the fibroblasts displayed a defect in import of peroxisomal matrix and membrane proteins, resulting in a total absence of peroxisomal remnants (Honsho et al., 1998; Shimozawa et al., 2002) , and very recently, several patients with a relatively mild clinical phenotype of which the fibroblasts showed enlarged, import-competent peroxisomes (Ebberink et al., 2010) . In total eight different mutations have been identified in the PEX16 gene of which one has not been reported previously (table 10) .
The PEX19 (MIM600279) gene encodes a mainly cytosolic protein that binds many peroxisomal membrane proteins, suggesting that PEX19 functions as a peroxisomal receptor for peroxisomal membrane proteins (Sacksteder et al., 2000) . The patients with a defect in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 F o r P e e r R e v i e w John Wiley & Sons, Inc. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 19 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 Ebberink et al., 2009b; Shimozawa et al., 1999b ) Reference sequence of PEX5L: GenBank accession number X84899. Nucleotide numbering starting at the first adenine of the translation initiation codon ATG. Chang et al., 1999; Gootjes et al., 2004c; Steinberg et al., 2004) 3 c.887delT p.L296PfsX5 (Steinberg et al., 2004) Huybrechts et al., 2008) 7 c.553C>T p.Gln185Ter (Shimozawa et al., 2004) 7 c.585+1G>T r.585+1_37ins 1 this study Reference sequence of PEX14: GenBank accession number NM_004565.2. Nucleotide numbering starting at the first adenine of the translation initiation codon ATG. (Honsho et al., 1998; South and Gould, 1999) All forward and reverse primers were tagged with a -21M13 (5'-GTAAAACGACGGCCAGT-3') sequence or M13rev (5'-CAGGAAACAGCTATGACC-3') sequence.
Human Mutation
Supplemental Table S2 . Primer sets used for PEX2 mutation analysis.
All forward and reverse primers were tagged with a -21M13 (5'-GTAAAACGACGGCCAGT-3') sequence or M13rev (5'-CAGGAAACAGCTATGACC-3') sequence.
Supplemental Table S3 . Primer sets used for PEX3 mutation analysis. All forward and reverse primers were tagged with a -21M13 (5'-GTAAAACGACGGCCAGT-3') sequence or M13rev (5'-CAGGAAACAGCTATGACC-3') sequence. All forward and reverse primers were tagged with a -21M13 (5'-GTAAAACGACGGCCAGT-3') sequence or M13rev (5'-CAGGAAACAGCTATGACC-3') sequence.
Supplemental
Supplemental Table S5 . Primer sets used for PEX10 mutation analysis. All forward and reverse primers were tagged with a -21M13 (5'-GTAAAACGACGGCCAGT-3') sequence or M13rev (5'-CAGGAAACAGCTATGACC-3') sequence.
Supplemental Table S6 . Primer sets used for PEX12 mutation analysis. All forward and reverse primers were tagged with a -21M13 (5'-GTAAAACGACGGCCAGT-3') sequence or M13rev (5'-CAGGAAACAGCTATGACC-3') sequence.
Supplemental Table S7 . Primer sets used for PEX13 mutation analysis 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 All forward and reverse primers were tagged with a -21M13 (5'-GTAAAACGACGGCCAGT-3') sequence or M13rev (5'-CAGGAAACAGCTATGACC-3') sequence.
Supplemental Table S11 . Primer sets used for PEX26 mutation analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
